Asset
LOTILANER
Tarsus Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07443202 | phase2 | enrolling_by_invitation | 2025-12-05 | 2026-12-31 | Tarsus Pharmaceuticals, Inc. | Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE) |
| NCT05838170 | phase2 | completed | 2023-03-01 | 2023-11-13 | Tarsus Pharmaceuticals, Inc. | Study of TP-04 in Participants With Papulopustular Rosacea |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| NDA 217603 | NDA | TARSUS PHARMACEUTICALS INC |
Marketed products (1)
- XDEMVY